Paolo D A Vignali

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Locally Advanced

Squamous Cell Carcinoma

Ejection Fraction

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Science immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Paolo D A Vignali, Jason John Luke
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
B Rhodes Ford, Paolo D A Vignali, Natalie L Rittenhouse, Nicole E Scharping, Ronal Peralta, Konstantinos Lontos, Andrew T Frisch, Greg M Delgoffe, Amanda C Poholek
Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. Science immunology 7 (74) (2022)